Welcome to our dedicated page for SciSparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc stock.
SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
SciSparc (SPRC)/b) reported that subsidiary Three U.S. patent applications have been published for combinations of lysergic acid diethylamide (LSD), ketamine and ibogaine with N‑acylethanolamines, including NeuroThera’s proprietary palmitoylethanolamide (PEA) technology. The filings describe potential therapeutic uses across mental health conditions such as depression and post‑traumatic stress disorder (PTSD), as well as pain and substance use disorders.
These applications build on a previously announced U.S. patent application for combinations of MDMA and N‑acylethanolamines targeting PTSD, anxiety and eating disorders. NeuroThera states that the maturing patent portfolio illustrates broader potential applications of its PEA technology with psychedelic compounds, and that the collaboration with Clearmind is intended to support development of safer, more effective treatments for common and growing mental‑health and substance use conditions.
SciSparc (SPRC) reported that majority-owned subsidiary NeuroThera Labs is pursuing U.S. FDA Orphan Drug Designation for SCI-110, its cannabinoid-based candidate for adults with Tourette Syndrome, and has engaged U.S. government and public affairs firm RK Strategies to support this regulatory and policy effort.
Orphan status in the United States is reserved for investigational therapies targeting diseases affecting fewer than 200,000 people and, if granted, can offer regulatory and commercial advantages. SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dosage form, targeting tic reduction and associated comorbid symptoms while aiming to limit side effects. NeuroThera has advanced SCI-110 into a Phase IIb program at three academic centers in the United States, Germany and Israel, following Phase IIa data showing an average tic reduction of 21% on the Yale Global Tic Severity Scale Total Tic Score.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) has reached enrollment of 26 children in the ongoing SCI‑210 clinical trial for autism spectrum disorder at Soroka Medical Center in Israel, out of a planned 60 participants aged five to 18.
The double‑blind, randomized, placebo‑controlled study is evaluating the safety and efficacy of SCI‑210, a proprietary combination of cannabidiol (CBD) and CannAmide, NeuroThera’s Palmitoylethanolamide-based formulation. Children receive treatment for 20 weeks, with primary endpoints including the ABC‑C parent questionnaire, clinician-rated CGI‑I assessment, and determination of optimal therapeutic dose.
The trial compares SCI‑210 with CBD monotherapy to assess whether the dual‑compound approach offers additional benefits. Designed in collaboration with the National Autism Research Center in Israel, the study is described as a key component of NeuroThera’s SCI‑210 program and part of its broader focus on neurological and neurodevelopmental conditions. According to SciSparc, following successful clinical development and regulatory approvals, NeuroThera plans to seek commercialization of SCI‑210, initially in Israel and then in other markets.
SciSparc (Nasdaq: SPRC) announced that Prof. Carmel Domshlak, an internationally recognized AI expert and Technion professor, will join its newly established Scientific Advisory Board for AI and Cybersecurity, effective September 1, 2026. This follows the company’s July 27, 2026 decision to target the Agentic AI market.
According to SciSparc, Prof. Domshlak’s appointment is intended to strengthen its scientific and technical foundation as it evaluates technologies, companies and opportunities in the rapidly evolving Agentic AI ecosystem. His research spans automated reasoning, sequential decision-making, action planning and multi-agent systems, with multiple ICAPS Influential Paper Awards.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) and collaborator Clearmind Medicine (Nasdaq: CMND) have advanced their partnership with U.S. publication of a patent application covering a novel combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for treating PTSD, anxiety and eating disorders.
According to SciSparc, the application, published by the U.S. Patent and Trademark Office, expands a joint intellectual property portfolio that now includes 13 published patent applications globally. The filing describes embodiments where PEA may influence MDMA’s therapeutic potency, dosing, side effects and therapeutic window. The development coincides with the U.S. FDA’s July 14, 2026 final guidance on psychedelic drug development, which explicitly includes MDMA and outlines clinical trial, safety and regulatory considerations, providing additional regulatory context for the collaboration’s MDMA-PEA program.
SciSparc (Nasdaq: SPRC) reported that majority-owned subsidiary NeuroThera Labs (TSXV: NTLX) completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million. SciSparc invested C$2.7 million, subscribing for 22,500,000 units at C$0.12 per unit, representing 50% of the financing.
Each unit includes one NeuroThera common share and one three-year warrant, with an acceleration feature tied to a potential Nasdaq listing. Following the financing, SciSparc holds approximately 44.6% of NeuroThera’s common shares, and its stake is valued at about C$30 million. NeuroThera plans to use the net proceeds for general working capital and corporate and administrative expenses.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) has been granted a Japanese patent for its pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” The patent covers proprietary combinations of 4-aminophenol derivatives, including paracetamol, with N-acylethanolamines.
According to NeuroThera, these compositions are designed to enhance analgesic and antipyretic performance and may allow lower effective dosing, potentially addressing dose-related side-effect concerns. The grant strengthens NeuroThera’s intellectual property portfolio and is described as a strategic milestone as it advances next-generation therapies for pain, fever, and related conditions in global markets.
SciSparc (Nasdaq: SPRC)/b) reported that subsidiary NeuroThera Labs (TSXV: NTLX) has initiated a U.S. Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, to study , a proprietary cannabinoid-based candidate for adult Tourette Syndrome.
According to SciSparc, SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dosage form, aiming to reduce tics and comorbid symptoms while minimizing side effects. The randomized, double-blind, placebo-controlled, cross-over Phase IIb trial is also underway at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel.
The study builds on Phase IIa data showing an average 21% tic reduction on the Yale Global Tic Severity Scale. Adults aged 18–65 will receive SCI-110 or placebo, with primary efficacy measured by tic severity changes at weeks 12 and 26 versus baseline and safety evaluated via adverse event monitoring.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs’ quantum sampling workflow platform for clinical trials data analytics has demonstrated a complete end-to-end hybrid quantum-classical workflow in a quantum simulation environment. The Platform processed real-world clinical data from secure ingestion and preparation through quantum-enabled analysis to biologically and clinically interpretable insights.
According to SciSparc, the proprietary framework is designed to enable quantum-enhanced sampling for continuous probability distributions in advanced statistical analyses of complex, high-dimensional biomedical and clinical trial datasets. Development plans include scaling supported datasets, further optimizing quantum algorithms, and running performance studies for clinical research, trial analytics and precision medicine. The Platform is advanced through CliniQuantum, in which NeuroThera holds 54.01%.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) has completed internal validation of a proprietary quantum sampling workflow within its clinical trials data analysis Platform. The workflow allows continuous probability distributions to be represented and analyzed in a quantum computing framework using a major S&P 500 company’s hybrid quantum-classical platform.
According to SciSparc, the validated workflow underpins a key part of the Platform’s computational architecture and is expected to expand capabilities for large-scale clinical and biomedical datasets. The methodology converts continuous data into quantum-operable energy landscapes, enabling Quantum Markov Chain Monte Carlo (QMCMC) sampling while preserving original statistical properties. Quantum dynamics generate proposals and classical logic enforces the target distribution, maintaining statistical guarantees. The Platform is advanced via CliniQuantum, a quantum-focused initiative in which NeuroThera holds 54.01%.